Startup | December 05, 2021
Apollo Health Ventures closes US $ 180 million fund
The fund aims at investing in companies that extends human healthspan
The fund aims at investing in companies that extends human healthspan
This further adds to Biocon’s portfolio of vertically integrated complex drug products
Researchers observed that the Pfizer/BioNTech and Moderna vaccines were 78% and 73% effective in preventing Covid-19 infections, respectively
This agreement marks a milestone for Baidu to use its strengths in computational biology to optimize mRNA vaccine and therapy designs
The companies expect to manufacture over 80 million does of the Covid-19 vaccine in 2022
In his new role as Managing Director India and Global Head, Partnerships and Innovative Finance, Singh will oversee the financial, human, and operational functions of the India office
.jpg)
Molbio Diagnostics has been the pioneer in providing access to molecular testing through its Truenat Real Time PCR platform. Sriram Natarajan, Director & CEO, of the company shares his experiences on the journey so far in an interview with Thomas C Thottathil
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
ImmunoACT has a portfolio of CAR-T therapy assets under various development stages for the treatment of multiple autoimmune diseases and oncology indications.
It is used for the treatment of advanced colorectal and gastric cancer
Subscribe To Our Newsletter & Stay Updated
